Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
| Autor: | Earl, H. M., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A-l., Gounaris, I., Abraham, J., Hughes-davies, L., Mcadam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L. |
|---|---|
| Přispěvatelé: | ARTemis Investigators Group |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Remission Induction
Breast Neoplasms Docetaxel Original Articles Genes erbB-2 Middle Aged bevacizumab Survival Analysis Neoadjuvant Therapy ARTemis RC0254 Early Diagnosis breast cancer Antineoplastic Combined Chemotherapy Protocols Breast Tumors Humans Female Taxoids Fluorouracil Cyclophosphamide Epirubicin neoadjuvant chemotherapy |
| Zdroj: | Annals of Oncology Earl, H M, Hiller, L, Dunn, J, Blenkinsop, C, Grybowicz, L, Vallier, A, Gounaris, I, Abraham, J, Hughes-davies, L, Mcadam, K, Chan, S, Ahmad, R, Hickish, T, Rea, D, Caldas, C, Bartlett, J M S, Cameron, D A, Provenzano, E, Thomas, J & Hayward, R L 2017, ' Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. ', Annals of Oncology . https://doi.org/10.1093/annonc/mdx173 |
| ISSN: | 1569-8041 0923-7534 |
| Popis: | Background The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the pathological complete response (pCR) rate. We present disease-free survival (DFS) and overall survival (OS) with central pathology review. Patients and methods Patients were randomized to 3 cycles of D followed by 3 cycles of FEC (D-FEC), ±4 cycles of Bev (Bev + D-FEC). DFS and OS were analyzed by treatment and by central pathology reviewed pCR and Residual Cancer Burden (RCB) class. Results A total of 800 patients were randomized [median follow-up 3.5 years (IQR 3.2–4.4)]. DFS and OS were similar across treatment arms [DFS hazard ratio (HR)=1.18 (95% CI 0.89–1.57), P = 0.25; OS HR = 1.26 (95% CI 0.90–1.76), P = 0.19). Both local pathology report review and central histopathology review confirmed a significant improvement in DFS and OS for patients who achieved a pCR [DFS HR = 0.38 (95% CI 0.23–0.63), P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|